Abstract
Overexpression of epidermal growth factor receptor (EGFR) is seen in a number of human tumors like prostate, colon, breast and ovarian. Their expression is correlated with vascularity and often difficult to diagnose. Though a number of active inhibitors and anticancer drugs against EGFR-tyrosine kinase are known, increase in resistance together with many side effects designate the need for new and improved treatments. Natural products and their analoges have significant contribution in the cancer drug discovery and development process. Therefore in the current review we mainly discuss design, synthesis and structural activity relationship of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin.
Keywords: Epidermal growth factor receptor, Natural origin, SAR.
Anti-Cancer Agents in Medicinal Chemistry
Title:Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Volume: 15 Issue: 8
Author(s): Harun M. Patel, Rajesh Rane, Neeta Thapliyal, Mahesh Palkar, Mahamadhanif Shaikh and Rajshekhar Karpoormath
Affiliation:
Keywords: Epidermal growth factor receptor, Natural origin, SAR.
Abstract: Overexpression of epidermal growth factor receptor (EGFR) is seen in a number of human tumors like prostate, colon, breast and ovarian. Their expression is correlated with vascularity and often difficult to diagnose. Though a number of active inhibitors and anticancer drugs against EGFR-tyrosine kinase are known, increase in resistance together with many side effects designate the need for new and improved treatments. Natural products and their analoges have significant contribution in the cancer drug discovery and development process. Therefore in the current review we mainly discuss design, synthesis and structural activity relationship of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin.
Export Options
About this article
Cite this article as:
Patel M. Harun, Rane Rajesh, Thapliyal Neeta, Palkar Mahesh, Shaikh Mahamadhanif and Karpoormath Rajshekhar, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (8) . https://dx.doi.org/10.2174/1871520615666150312100259
DOI https://dx.doi.org/10.2174/1871520615666150312100259 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate
Medicinal Chemistry New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry Smart Electrospun Nanofibers for Controlled Drug Release: Recent Advances and New Perspectives
Current Pharmaceutical Design Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry Malignant Intracranial High Grade Glioma and Current Treatment Strategy
Current Cancer Drug Targets Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Gene Therapy for Gastrointestinal and Liver Cancers: Past Experience, Current Status and Future Perspectives)
Current Gene Therapy